Transplanted Pig Kidney Still Working After a Record

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-03T22:35:28.788Z • Permanent link

Dr. David Liu, a renowned geneticist at Harvard University, has made headlines by successfully transplanting a gene-edited pig kidney into a human patient. The recipient, a 57-year-old man, received the kidney on December 16, 2023, at Massachusetts General Hospital in Boston. The groundbreaking procedure marks a significant milestone in the development of xenotransplantation, a field that has been years in the making. The pig kidney, which was genetically engineered to be compatible with the human immune system, has been functioning normally, providing a vital lifeline to a patient who would have otherwise been left waiting for a human donor.

Dr. Liu's team at Editas Medicine, a biotech firm that specializes in CRISPR gene editing, had been working on the project for several years. They had already demonstrated the safety and efficacy of their gene-edited pig kidneys in animal trials. However, the human trial was a much more complex and challenging endeavor. The researchers had to overcome numerous technical hurdles, including ensuring the kidney's function and preventing rejection by the human immune system. The patient, who remains anonymous, was carefully selected and monitored throughout the procedure.

The success of the transplant has sent shockwaves through the medical community, with many experts hailing it as a major breakthrough. The procedure has the potential to revolutionize the treatment of kidney failure, which affects millions of people worldwide. According to the International Society of Nephrology, over 1 million people in the United States alone are on the waiting list for a kidney transplant. The development of gene-edited pig kidneys could provide a much-needed solution to this crisis, offering a potential alternative to human donor kidneys.

The impact of gene-edited pig kidneys on the global healthcare landscape cannot be overstated. Companies like United Therapeutics, a biotech firm that specializes in xenotransplantation, are already working on scaling up the production of gene-edited pig kidneys. The technology has the potential to disrupt the kidney transplant market, which is currently dominated by human donor kidneys. According to a report by MarketsandMarkets, the global xenotransplantation market is expected to grow from $1.4 billion in 2022 to $4.6 billion by 2027, driven by increasing demand for alternative organ sources.

The development of gene-edited pig kidneys also has significant implications for the research community. Scientists are already exploring the use of xenotransplantation to treat other diseases, including liver and heart failure. The technology has the potential to revolutionize the field of regenerative medicine, offering new possibilities for the treatment of a wide range of diseases. As researchers continue to refine the technology, we can expect to see significant breakthroughs in the coming years.

The development of gene-edited pig kidneys is part of a larger trend towards the use of xenotransplantation in human medicine. This approach has been explored in various forms over the years, but it has only gained significant traction in recent years. The use of xenotransplantation has been pioneered by companies like Organovo, a biotech firm that specializes in 3D printing of human organs. However, the technology has also faced significant regulatory hurdles, including concerns over the safety and efficacy of the organs.